TheEdgeResearch
Home / Stocks / HYBT

Heyu Biological Technology Corporation (HYBT)

OTC Healthcare Medical - Devices
$0.35 ▼ -41.67%
Market Cap
$361.4M
Sector
Healthcare
Industry
Medical - Devices
Beta
-17.89
52-Wk Range
0.002-3.4
CEO
Ban Siong Ang
Country
CN
Currency
USD

Heyu Biological Technology Corporation operates in the Medical - Devices industry of the Healthcare sector, headquartered in Xiamen, CN. The stock last traded at $0.35, down 41.67% on the session, giving a market capitalisation of $361.4M. On trailing twelve-month figures it carries a trailing P/E of 175.00, a net margin of 8.8%. Its beta of -17.89 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
175.00
Price / Sales
31.89
Price / Book
4.29
EV / EBITDA
268.14
Gross margin
17.1%
Operating margin
10.0%
Net margin
8.8%
Return on equity
—
Debt / equity
0.19
Current ratio
0.85
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
—
IPO date
1999-12-06
Headquarters
Xiamen, CN
About Heyu Biological Technology Corporation

Heyu Biological Technology Corporation, alongside its subsidiaries, focuses on the research, development, and production of healthcare equipment. A key area of its present work involves developing the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber, a medical device intended for cancer treatment. This innovative equipment is designed to induce cold nuclear fusion via cosmic ray muons within a contained environment to combat the disease. The company, incorporated in 1987 and headquartered in Xiamen, People's Republic of China, was formerly known as Pacific WebWorks, Inc., before adopting its current name, Heyu Biological Technology Corporation, in June 2018.

Comparable companies

Heyu Biological Technology Corporation is most often compared with the following Healthcare names:

BTMDCSSPFDFHLGUERFHTLZFORRRYPKBFFSMDCFSSIITBGNF
More research on HYBT
HYBT technical analysis HYBT TheEdge Score Compare against peers
Open full interactive analysis & DCF →